Biodesix Past Earnings Performance
Past criteria checks 0/6
Biodesix's earnings have been declining at an average annual rate of -20.8%, while the Healthcare industry saw earnings growing at 4.6% annually. Revenues have been growing at an average rate of 9.2% per year.
Key information
-20.8%
Earnings growth rate
88.4%
EPS growth rate
| Healthcare Industry Growth | 8.5% |
| Revenue growth rate | 9.2% |
| Return on equity | -1,138.6% |
| Net Margin | -106.2% |
| Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
With A 25% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For
Mar 03
Biodesix, Inc.'s (NASDAQ:BDSX) P/S Is Still On The Mark Following 28% Share Price Bounce
Jan 04It's Down 28% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks
Jul 16A Second Look At Biodesix
Oct 18Biodesix expects Q3 revenue above the consensus
Oct 11Biodesix GAAP EPS of -$0.40 beats by $0.07, revenue of $10.95M beats by $2.12M
Aug 04Biodesix: Bad Diagnosis
May 26Analysts' Revenue Estimates For Biodesix, Inc. (NASDAQ:BDSX) Are Surging Higher
Mar 15Need To Know: Analysts Just Made A Substantial Cut To Their Biodesix, Inc. (NASDAQ:BDSX) Estimates
Nov 25Bearing In On Biodesix
Sep 13Time To Worry? Analysts Are Downgrading Their Biodesix, Inc. (NASDAQ:BDSX) Outlook
Aug 16Biodesix: Continued Concerns After The Boom-Bust Cycle
Jul 14Biodesix pops 6% on launch of SARS CoV-2 Neutralization Antibody Test
Jun 15Biodesix announces strategic partnership with Datavant
Jun 04Biodesix enrolls first patient in lung cancer study
May 26Revenue & Expenses BreakdownBeta
How Biodesix makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 49 | -52 | 67 | 10 |
| 30 Sep 23 | 44 | -63 | 68 | 12 |
| 30 Jun 23 | 42 | -66 | 67 | 13 |
| 31 Mar 23 | 41 | -69 | 66 | 13 |
| 31 Dec 22 | 38 | -65 | 61 | 13 |
| 30 Sep 22 | 36 | -58 | 58 | 12 |
| 30 Jun 22 | 31 | -56 | 57 | 13 |
| 31 Mar 22 | 32 | -52 | 53 | 13 |
| 31 Dec 21 | 55 | -43 | 51 | 13 |
| 30 Sep 21 | 74 | -34 | 49 | 13 |
| 30 Jun 21 | 77 | -32 | 43 | 12 |
| 31 Mar 21 | 69 | -29 | 39 | 11 |
| 31 Dec 20 | 46 | -31 | 35 | 11 |
| 30 Sep 20 | 27 | -33 | 29 | 10 |
| 30 Jun 20 | 22 | -34 | 30 | 10 |
| 31 Mar 20 | 23 | -33 | 31 | 11 |
| 31 Dec 19 | 25 | -31 | 31 | 10 |
| 31 Dec 18 | 20 | -26 | 26 | 8 |
Quality Earnings: BDSX is currently unprofitable.
Growing Profit Margin: BDSX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BDSX is unprofitable, and losses have increased over the past 5 years at a rate of 20.8% per year.
Accelerating Growth: Unable to compare BDSX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BDSX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (12.5%).
Return on Equity
High ROE: BDSX has a negative Return on Equity (-1138.56%), as it is currently unprofitable.